The CREDENCE study was the first study undertaken in individuals with T2D and established CKD, who were randomized to receive the SGLT2 inhibitor, canagliflozin or placebo, on top of a comprehensive standard of care (11). This evidence concerns the gene SLC5A2 and chronic kidney disease.